Dark

Check out our API

ALRN
Aileron Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Jan 10, 2025

2.11USD+9.326%(+0.18)63,081

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-1.93)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 5, 2022

08:11AM EST Aileron Therapeutics Provides Business Update And Outlines 2022 Strategic Priorities To Deliver Key Milestones Benzinga

08:04AM EST Aileron Therapeutics Provides Business Update GlobeNewswire Inc

Jan 4, 2022

08:45AM EST Aileron Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire Inc

07:00AM EST EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 22nd Emerging Growth Conference. GlobeNewswire Inc

Dec 20, 2021

10:57AM EST Aileron Therapeutics (NASDAQ:ALRN) today issued the following statementregarding the passing of Nobel Laureate Robert H. Grubbs, Ph.D., who served as a member of the company's Scientific Advisory Board since 2011. GlobeNewswire Inc

Nov 12, 2021

07:54AM EST Aileron Therapeutics Q3 EPS $(0.07) Up From $(0.13) YoY Benzinga

07:50AM EST Aileron Therapeutics Reports Third Quarter 2021 Financial Results GlobeNewswire Inc

Oct 7, 2021

09:24AM EDT Aileron Therapeutics Presents Data At AACR-NCI-EORTC International Conference Demonstrating ALRN-6924's Activity As Radioprotective Agent In Preclinical Models Of Acute Radiation-Induced Toxicity Benzinga

09:23AM EDT -- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agentfor patients with p53-mutated cancer undergoing chemotherapy -- GlobeNewswire Inc

Sep 30, 2021

04:31PM EDT Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021 Benzinga

04:30PM EDT Aileron Therapeutics Announces Presentation of New Preclinical GlobeNewswire Inc

Sep 16, 2021

08:16AM EDT Aileron Therapeutics Highlights Presentation Of ALRN-6924 Clinical Data At ESMO Virtual Congress 2021 Benzinga

08:15AM EDT Aileron Therapeutics Presents New Clinical Data at ESMO Virtual GlobeNewswire Inc

Sep 12, 2021

04:04PM EDT The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs Benzinga

Sep 10, 2021

08:35AM EDT Aileron Therapeutics To Present New Clinical Data At ESMO Virtual Congress 2021 Supporting ALRN-6924 Sept. 16-21 Benzinga

08:30AM EDT -- Preliminary findings from ongoing Phase 1 healthy volunteer study will include data relating to mechanism of action; optimal dose; and time to onset, duration and magnitude of pharmacodynamic effects -- Final data from completed Phase 1b study in patients with small cell lung cancer (SCLC) receiving topotecan supporting best-in-class potential of ALRN-6924 GlobeNewswire Inc

Sep 7, 2021

04:05PM EDT Aileron Therapeutics to Present at Upcoming H.C. Wainwright GlobeNewswire Inc

Aug 27, 2021

09:48AM EDT Aileron Unveils Initial Data For Its Chemo Protective Agent Benzinga

07:46AM EDT Aileron Therapeutics Highlights Presentation Of Initial Findings From Ongoing Healthy Volunteer Study Of ALRN-6924 At ISEH 50th Annual Scientific Meeting Benzinga

07:45AM EDT Aileron Therapeutics Presents Initial Findings from Ongoing GlobeNewswire Inc

Aug 25, 2021

07:30AM EDT The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug Benzinga

Aug 11, 2021

04:22PM EDT Aileron Therapeutics Q2 EPS $(0.06) Up From $(0.14) YoY Benzinga

04:20PM EDT -- Initiated Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC); first interim safety data expected at end of 2021 and topline results mid-2022 GlobeNewswire Inc

Jul 8, 2021

08:15AM EDT Aileron Therapeutics to Participate in Fireside Chat at the GlobeNewswire Inc

Jul 1, 2021

01:39PM EDT Aileron Launches Early-Stage Study For Chemoprotective Candidate In Lung Cancer Settings Benzinga

08:12AM EDT Aileron Therapeutics Begins Phase 1b Trial Of ALRN-6924 In Patients With Advanced Non-Small Cell Lung Cancer RTTNews

08:06AM EDT Aileron Therapeutics Announces Initiation Of Randomized, Double-Blind, Placebo-Controlled Trial Of ALRN-6924 In Patients With Advanced Non-Small Cell Lung Cancer Benzinga

08:00AM EDT Aileron Therapeutics Announces Initiation of Randomized, GlobeNewswire Inc

Jun 24, 2021

07:12AM EDT Aileron Therapeutics to be Added to the Russell Microcap Index Benzinga

07:00AM EDT Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, announced today that it is set to join the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, 2021. GlobeNewswire Inc

May 19, 2021

07:04AM EDT Aileron Therapeutics to Host KOL Virtual Investor Event Discussing 'Opportunity for New Paradigm to Protect Cancer Patients from Chemotherapy-Induced Toxicities' May 26 Benzinga

07:00AM EDT -- Fireside chat, moderated by Soumit Roy, Ph.D. of JonesTrading, will be held onWednesday, May 26, 2021 at 11:00 am ET-- GlobeNewswire Inc

May 11, 2021

04:58PM EDT Aileron Therapeutics Q1 EPS $(0.08) Up From $(0.24) YoY Benzinga

04:18PM EDT -- Progressing ALRN-6924: on track to initiate Phase 1b randomized placebo-controlled trial in patients with p53-mutated non-small cell lung cancer in 2nd quarter 2021 with early interim read-out expected at end of 2021 GlobeNewswire Inc

Apr 6, 2021

09:37AM EDT Aileron Therapeutics US Patent & Trademark Office Abstract For Co.'s 'Peptidomimetic macrocycles' Benzinga

Mar 24, 2021

04:37PM EDT -- 2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients GlobeNewswire Inc

Mar 4, 2021

08:30AM EST Aileron Therapeutics to Present at 2021 H.C. Wainwright Global GlobeNewswire Inc

Mar 2, 2021

07:23AM EST Aileron Therapeutics Expands Enrollment Target For Upcoming Phase 1b Clinical Trial Of ALRN-6924 In Patients With Advanced Non-Small Cell Lung Cancer From 40 To 60 Patients Benzinga

07:00AM EST --Placebo-controlled trial anticipated to enroll 60 patients with advanced p53-mutatedNSCLC undergoing treatment with first-line carboplatin plus pemetrexed -- GlobeNewswire Inc

Feb 2, 2021

05:06AM EST Aileron Therapeutics Awarded U.S. Patent 10,905,739 'Peptidomimetic macrocycles and formulations thereof' Benzinga

Jan 11, 2021

06:30AM EST -- Several existing Aileron investors, including Satter Medical Technology Partnersand Lincoln Park Capital Fund, LLC, also participated in the offering -- GlobeNewswire Inc

Jan 8, 2021

04:21PM EST Aileron Therapeutics Director Muneer Satter Purchased 9M Shares @$1.10/Share that Were Sold as Part of an Offering by the Co Benzinga

04:18PM EST AILERON THERAPEUTICS INC: Satter Muneer A (Director, See Remarks) Buys 9,000,000 @ Avg Price: $1.10 (Form4) Benzinga

Jan 6, 2021

09:53AM EST Aileron Therapeutics Inc.(ALRN) said that it has reached definitive agreements with fundamental healthcare investors for the purchase and sale of 32.63 million of its shares of common stock at a purchase price of $1.10 per share in a registered direct offering. RTTNews

09:30AM EST Aileron Therapeutics Announces $35.9M Direct Offering At $1.10/Share Benzinga

09:30AM EST Aileron Therapeutics Announces $35.9 Million Registered Direct GlobeNewswire Inc

Dec 21, 2020

08:12AM EST Aileron Therapeutics Provides Business Update And Outlines Strategic Priorities For 2021 RTTNews

08:07AM EST Aileron Therapeutics Expects To Initiate Phase 1B Randomized, Placebo-controlled Clinical Trial Of Novel Chemoprotective Agent ALRN-6924 In Patients With Advanced Non-small Cell Lung Cancer In FY21 Benzinga

08:00AM EST -- Ailerons 2021 strategic priorities aim to advance its vision to bring chemoprotection to all patients with p53-mutant cancers regardless of cancer indication or chemotherapy. Key anticipated milestones include: GlobeNewswire Inc

Oct 26, 2020

02:37PM EDT Mid-Afternoon Market Update: Crude Oil Down Over 3%; SAP Shares Slide On Lowered Outlook Benzinga

12:34PM EDT Mid-Day Market Update: Dow Tumbles 650 Points; Lianluo Smart Shares Climb Benzinga

10:35AM EDT Why Aileron's Stock Is Trading Lower Today Benzinga

Oct 24, 2020

04:36AM EDT Aileron Therapeutics Announces Proof-of-Concept Clinical Data from GlobeNewswire Inc

Oct 21, 2020

08:04AM EDT The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga

Oct 20, 2020

09:25AM EDT Aileron Therapeutics to Host Conference Call to Discuss Results GlobeNewswire Inc

Oct 12, 2020

07:05AM EDT Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium Benzinga

07:00AM EDT Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 GlobeNewswire Inc

Oct 5, 2020

05:06PM EDT Aileron Therapeutics S-1 Shows Registration For 10.55M Share Common Stock Offering Via Selling Shareholders Benzinga

Sep 29, 2020

07:03AM EDT Health Canada Approves REBLOZYL, New Class of Treatment for Adult Patients Living with Beta-Thalassemia Benzinga

Sep 21, 2020

06:07PM EDT Aileron Therapeutics, Inc. (NASDAQ:ALRN), today announced it has entered into a common stock purchase agreement (Purchase Agreement) for up to$15 millionwith Lincoln Park Capital Fund, LLC (LPC), aChicago-based institutional investor and current shareholder. GlobeNewswire Inc

Sep 10, 2020

08:45AM EDT Aileron Therapeutics to Present at Upcoming H.C. Wainwright GlobeNewswire Inc

Aug 5, 2020

05:02PM EDT Aileron Therapeutics Q2 EPS $(0.14) Up From $(0.26) YoY Benzinga

Aug 3, 2020

08:10AM EDT Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences this month. GlobeNewswire Inc

08:08AM EDT Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924 Benzinga

08:00AM EDT Aileron Therapeutics Announces Completion of Enrollment in Dose GlobeNewswire Inc

Share